“Immunogenicity of Guselkumab (GUS) Among Psoriasis Patients in VOYAGE (VOY) 1&2 Studies” (2022) SKIN The Journal of Cutaneous Medicine, 6(2), p. s11. doi:10.25251/skin.6.supp.11.